BSA
BMRN icon

Braun Stacey Associates’s BioMarin Pharmaceuticals BMRN Stock Holding History

Braun Stacey Associates’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,750
Closed -$863K – 116
2023
Q3 		$863K Sell
9,750
-177,727
-95% -$15.8M 0.04% 104
2023
Q2 		$16.3M Sell
187,477
-193,853
-51% -$18.2M 0.76% 61
2023
Q1 		$37.1M Buy
381,330
+171,529
+82% +$17.8M 0.97% 41
2022
Q4 		$21.7M Buy
209,801
+38,883
+23% +$3.65M 1.24% 21
2022
Q3 		$14.5M Buy
+170,918
New +$15.2M 0.88% 53

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Braun Stacey Associates's BMRN Position: Q4 2023 in Review

Braun Stacey Associates sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 9,750 shares — an estimated $863K sold.

Braun Stacey Associates first reported a position in BMRN in Q3 2022 and held it in 5 quarters. The position peaked at $37.1M in Q1 2023. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

  • Braun Stacey Associates reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Braun Stacey Associates sold 9,750 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $863K.
  • Braun Stacey Associates first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Braun Stacey Associates's BioMarin Pharmaceuticals position peaked at $37.1M in Q1 2023.
  • 547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Braun Stacey Associates's 13F filing for Q4 2023, filed 23 Jan 2024.